This study was conducted using NSCLC (n = 113), CRC (n = 76) and MELA cases (n = 16) as the primary aim was to replace the conventional methods for EGFR, KRAS, NRAS and BRAF mutation analysis. This evidence concerns the gene EGFR and colorectal carcinoma.